rs8720
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma</span> (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
rs7960917
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
In conclusion, minor allele of rs3025039, rs3212986, and rs712 polymorphisms increases the risk of CRC in the East Asian population, and heterozygote model of rs731236 polymorphism shows protective effect in the Middle East population.
|
31637880 |
2019 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Comparison of the data from patients with control group showed that polymorphism of rs712 in <i>KRAS</i> gene was protective factor, which was associated with susceptibility for CRC.
|
31156795 |
2019 |
rs712
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
|
23975373 |
2014 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
rs397517040
|
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient.
|
24594115 |
2014 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer.
|
30568222 |
2019 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Biallelic mutations in MUTYH gene were detected in 3/12 (25%) remaining subjects with polyposis and in 6/90 (6.7%) patients with colorectal cancer (CRC) carrying KRAS p.G12C substitution, but not in 231 early-onset CRC cases negative for KRAS p.G12C allele.
|
29406563 |
2018 |
rs121913530
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.
|
23209813 |
2012 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.
|
26662311 |
2016 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer.
|
22753589 |
2012 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The results of the KRAS mutational analysis have shown that the majority of somatic mutations in the KRAS affect only one codon, mainly codon 12(p.G12D) with low frequency in adenomas (13.3%) versus CRCs (36%).
|
30997628 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association.
|
10398103 |
1999 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The inducible somatic KRAS mutation (G12D) was observed in nine (36%) of CRC patients, and in two (13.3%) of adenoma patients.
|
31692030 |
2020 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers.
|
26701267 |
2016 |
rs121913529
|
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
|
25359494 |
2015 |